Market News AIOpen the app

SELLAS Life Sciences Announces Positive Topline Results from Pivotal Phase 3 REGAL Trial

TrialRead the original at quantisnow.com
Good for SLS

SELLAS said its trial met its main goal and GPS lowered the risk of death. Longer survival supports GPS, though FDA approval has not been granted.

SLS · SELLAS Life Sciences Group, Inc.

AI read · Good for SLS

The AI's read

The results give GPS evidence that it can help patients live longer than the treatments used for comparison. This could strengthen SELLAS's case with the FDA, but approval has not been granted. The company still plans to discuss a possible path with the agency and prepare an application.

Get alerts for SLS

Follow SELLAS Life Sciences Group, Inc. (SLS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SLS
Free on the App Store and Google Play, or on the web.